JP2012530060A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530060A5
JP2012530060A5 JP2012515161A JP2012515161A JP2012530060A5 JP 2012530060 A5 JP2012530060 A5 JP 2012530060A5 JP 2012515161 A JP2012515161 A JP 2012515161A JP 2012515161 A JP2012515161 A JP 2012515161A JP 2012530060 A5 JP2012530060 A5 JP 2012530060A5
Authority
JP
Japan
Prior art keywords
pharmacological agent
peptide
seq
agent according
mast cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012515161A
Other languages
English (en)
Japanese (ja)
Other versions
JP5886192B2 (ja
JP2012530060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/038226 external-priority patent/WO2010144742A2/en
Publication of JP2012530060A publication Critical patent/JP2012530060A/ja
Publication of JP2012530060A5 publication Critical patent/JP2012530060A5/ja
Application granted granted Critical
Publication of JP5886192B2 publication Critical patent/JP5886192B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012515161A 2009-06-10 2010-06-10 内在化ペプチド連結薬剤と抗炎症剤との共投与 Expired - Fee Related JP5886192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18594309P 2009-06-10 2009-06-10
US61/185,943 2009-06-10
PCT/US2010/038226 WO2010144742A2 (en) 2009-06-10 2010-06-10 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134712A Division JP6238934B2 (ja) 2009-06-10 2015-07-03 内在化ペプチド連結薬剤と抗炎症剤との共投与

Publications (3)

Publication Number Publication Date
JP2012530060A JP2012530060A (ja) 2012-11-29
JP2012530060A5 true JP2012530060A5 (https=) 2013-07-04
JP5886192B2 JP5886192B2 (ja) 2016-03-16

Family

ID=43309471

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012515161A Expired - Fee Related JP5886192B2 (ja) 2009-06-10 2010-06-10 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2015134712A Expired - Fee Related JP6238934B2 (ja) 2009-06-10 2015-07-03 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2017179192A Expired - Fee Related JP6775478B2 (ja) 2009-06-10 2017-09-19 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2020074428A Active JP7209364B2 (ja) 2009-06-10 2020-04-17 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2022170797A Pending JP2023017813A (ja) 2009-06-10 2022-10-25 内在化ペプチド連結薬剤と抗炎症剤との共投与

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015134712A Expired - Fee Related JP6238934B2 (ja) 2009-06-10 2015-07-03 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2017179192A Expired - Fee Related JP6775478B2 (ja) 2009-06-10 2017-09-19 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2020074428A Active JP7209364B2 (ja) 2009-06-10 2020-04-17 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2022170797A Pending JP2023017813A (ja) 2009-06-10 2022-10-25 内在化ペプチド連結薬剤と抗炎症剤との共投与

Country Status (16)

Country Link
US (4) US8933013B2 (https=)
EP (2) EP3682895A1 (https=)
JP (5) JP5886192B2 (https=)
AU (1) AU2010259986B2 (https=)
CA (2) CA2765171C (https=)
CY (1) CY1122584T1 (https=)
DK (1) DK2440231T3 (https=)
ES (1) ES2765281T3 (https=)
HR (1) HRP20192230T1 (https=)
HU (1) HUE046640T2 (https=)
LT (1) LT2440231T (https=)
PL (1) PL2440231T3 (https=)
PT (1) PT2440231T (https=)
SI (1) SI2440231T1 (https=)
SM (1) SMT202000056T1 (https=)
WO (1) WO2010144742A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) * 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
EP3682895A1 (en) 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
PH12012500565B1 (en) 2009-09-22 2018-01-12 Medicago Inc Method of preparing plant-derived proteins
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
ES2912042T3 (es) 2011-06-24 2022-05-24 Nono Inc Terapia de combinación para isquemia
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
CA2892965C (en) * 2012-11-28 2021-06-01 Nono Inc. Lyophilized formulation of tat-nr2b9c
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation
AU2016382134B2 (en) 2015-12-28 2022-09-22 Idemitsu Kosan Co., Ltd. Peptide tag and tagged protein including same
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
HRP20250272T1 (hr) 2017-10-19 2025-04-25 Teijin Pharma Limited Derivati benzimidazola i njihova uporaba
US20230055441A1 (en) * 2020-01-09 2023-02-23 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
US20240301003A1 (en) 2021-01-08 2024-09-12 Nono Inc. Plasmin-resistant peptides for improved therapeutic index

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
EP1159418A2 (en) 1998-12-11 2001-12-05 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1601380A1 (en) 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US20050256065A1 (en) * 2004-01-26 2005-11-17 Permasight Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
KR101384572B1 (ko) 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
DK2043671T3 (da) * 2006-07-11 2020-06-15 Nono Inc Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
CN101842107B (zh) 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
ES2328776B1 (es) 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
EP3682895A1 (en) * 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor

Similar Documents

Publication Publication Date Title
JP2012530060A5 (https=)
US8569235B2 (en) Treatment of kidney disorders with VIP fragments
US8933013B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP2011506328A5 (https=)
JP2013521231A5 (https=)
RU2014126484A (ru) Нацеленные соединения лизосомальных ферментов
IL224609A (en) Intact and peptide intestinal fragments and methods of use
JP2014515747A5 (https=)
WO2019080919A1 (zh) 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法
CN105451756A (zh) 在治疗马凡氏综合征及其相关病症中的血管紧张素肽
JP5283106B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP2016500001A5 (https=)
JP5477794B2 (ja) エンドキニンｃ／ｄ由来のペプチド
CN106232621A (zh) 用于治疗癌症的168a‑t2的多肽片段及包含其的组合物
JP2015533821A5 (https=)
ES2639838T3 (es) Péptidos inhibidores de la interacción entre ASF1 y las histonas, y sus usos
JP2008156312A (ja) サブスタンスｐに対するペプチド由来のアンタゴニストの開発
JP2009500314A5 (https=)
HK1160598B (en) Compositions and methods for treatment of kidney disorders